#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant fibrous histiocytoma Cardiac failure acute Hepatitis D Retinopathy proliferative Osteochondrodysplasia Stevens-Johnson syndrome Malignant neoplasm of choroid Neuropathy peripheral Colon cancer Congenital growth hormone deficiency Myeloproliferative neoplasm Richter's syndrome B-cell lymphoma Endometrial cancer recurrent Neurofibromatosis More trials…

    Learn about Rare Diseases

    Ornithine transcarbamoylase deficiency Waldenstrom’s macroglobulinaemia – Treatment Congenital generalised lipodystrophy – Diagnostics Synovial sarcoma metastatic – Trials in Disease Uterine leiomyosarcoma – Diagnostics Marginal zone lymphoma refractory – Basic Information Hairy cell leukaemia – Basic Information Hereditary hypophosphataemic rickets – Life with Disease Glomerulonephritis membranous – Treatment Piriformis syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Darovasertib Linerixibat Enx-101 Potassium Chloride Tobevibart HYDROGEN PEROXIDE Macrogol 4000 Jnj-64042056 Ammonium Chloride Bp Dornase Alfa Metoprolol Tartrate Haloperidol Decanoate Mexiletine Chlorpromazine Hydrochloride Riliprubart Carboplatin Tiotropium Imatinib Phenol, Liquefied Ro7269162 More therapies…

    Learn about Your Condition

    Systemic sclerosis pulmonary Hypopituitarism Thrombocytopenia Bone marrow disorder Iron overload Hypogonadism male Oesophageal achalasia Myositis Radiation skin injury Cirrhosis alcoholic Giant cell arteritis Graves' disease Plasmablastic lymphoma Cleft lip and palate Muscle spasticity More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Triple negative breast cancer

  • Study on Imatinib for Patients with Triple Negative Breast Cancer to Convert it to ER-Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Imatinib
    Sweden

  • Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Capecitabine
    • Pembrolizumab
    Belgium France Germany Ireland Italy Spain

  • Assessing the prognostic value of PSMA‑T4 SPECT/CT imaging in patients with triple‑negative breast cancer undergoing neoadjuvant therapy

    Not yet recruiting

    4 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Poland

  • Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Carboplatin
    • Cyclophosphamide Monohydrate
    France

  • Safety and Tolerability of Lutetium‑177 Vipivotide Tetraxetan Combined with Gozetotide in Women with Metastatic Triple‑Negative Breast Cancer

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Gozetotide
    Germany

  • Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer male
    • Triple negative breast cancer
    • Breast cancer female
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Pembrolizumab
    Germany
Previous Page
1 … 3 4 5 6 7 … 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!